Spyre Therapeutics (SYRE) Cash & Equivalents (2015 - 2026)

Spyre Therapeutics has reported Cash & Equivalents for 12 years, with the latest figure at $97.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 107.66% year-over-year to $97.2 million; the trailing twelve-month figure through Mar 2026 stood at $97.2 million (up 107.66% YoY), and the FY2025 full-year result was $85.7 million, down 2.29% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $97.2 million, up from $85.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $235.4 million in Q2 2023, with the low at $14.6 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $87.2 million across 5 years, with a median of $69.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 81.76% — and 2024, when it surged 545.67%.
• Spyre Therapeutics' Cash & Equivalents stood at $34.9 million in 2022, then surged by 441.82% to $188.9 million in 2023, then plunged by 53.55% to $87.7 million in 2024, then fell by 2.29% to $85.7 million in 2025, then rose by 13.37% to $97.2 million in 2026.
• The last three Cash & Equivalents figures came in at $97.2 million (Q1 2026), $85.7 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.